Alaunos Therapeutics
TCRT
150 hedge funds and large institutions have $423M invested in Alaunos Therapeutics in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 55 increasing their positions, 38 reducing their positions, and 24 closing their positions.
71% more call options, than puts
Call options by funds: $5.06M | Put options by funds: $2.95M
50% more capital invested
Capital invested by funds: $281M → $423M (+$141M)
45% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 38
0.02% more ownership
Funds ownership: 0.35% → 0.36% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 156 → 150 (-6)
17% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$14.3M |
| 2 |
JP Morgan Chase
New York
|
+$11M |
| 3 |
Citigroup
New York
|
+$2.58M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.24M |
| 5 |
Rafferty Asset Management
New York
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MVP
Miller Value Partners
Sarasota,
Florida
|
-$2.62M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.22M |
| 3 |
SG Americas Securities
New York
|
-$2.17M |
| 4 |
Millennium Management
New York
|
-$2.08M |
| 5 |
Morgan Stanley
New York
|
-$1.34M |
TCRT Hedge Fund Activity: Q1 2021 in Review
150 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2021, worth a combined $423M — up 50% from $281M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of TCRT and 20 opened new positions — a net loss of 4 holders — while 38 trimmed existing stakes and 55 added.
The largest buyer was State Street, adding an estimated $14.3M. The largest seller was Miller Value Partners, cutting an estimated $2.62M.
- 150 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2021, down from 156 in Q4 2020.
- Funds reported $423M of Alaunos Therapeutics stock for Q1 2021, up 50% quarter-over-quarter.
- 20 funds opened new Alaunos Therapeutics positions in Q1 2021 and 24 closed out, a net change of -4 holders.
- The largest Alaunos Therapeutics buyer in Q1 2021 was State Street, an estimated $14.3M added.
- The largest Alaunos Therapeutics seller in Q1 2021 was Miller Value Partners, an estimated $2.62M sold.
Based on aggregated 13F filings for Q1 2021.